pbtz169
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT03036163)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pbtz169
- pbtz169
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03776500 | Phase 1 | Feb 21, 2019 | Bill and Melinda Gates Foundation, Innovative Medicines for Tuberculosis |
| NCT04150224 | Phase 1 | Jul 3, 2018 | Nearmedic Plus LLC |
| NCT03423030 | Phase 1 | Dec 5, 2017 | Bill and Melinda Gates Foundation, Innovative Medicines for Tuberculosis |
| NCT03334734 | Phase 2 | Dec 16, 2016 | Nearmedic Plus LLC, OCT Clinical Trials |
| NCT03036163 | Phase 1 | Jan 1, 2016 | Nearmedic Plus LLC, OCT Clinical Trials |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nearmedic Plus LLC | For profit | 3 | 3 | 2 | 2016 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 2 | 0 | 1 | 2017 |
| Innovative Medicines for Tuberculosis | Academic/Hospital | 2 | 2 | 1 | 2017 |
| OCT Clinical Trials | For profit | 2 | 0 | 2 | 2016 |
4 organizations
Page 1 / 1